Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia.

Evensen NA, Madhusoodhan PP, Meyer J, Saliba J, Chowdhury A, Araten DJ, Nersting J, Bhatla T, Vincent TL, Teachey D, Hunger SP, Yang J, Schmiegelow K, Carroll WL.

Haematologica. 2018 May;103(5):830-839. doi: 10.3324/haematol.2017.176362. Epub 2018 Feb 15.

2.

No evidence of hypermutability in red cells from patients with paroxysmal nocturnal hemoglobinuria using the XK gene.

Araten DJ, Zamechek L, Halverson G.

Haematologica. 2014 Aug;99(8):e142-4. doi: 10.3324/haematol.2013.099457. Epub 2014 May 9. No abstract available.

3.

Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria.

Araten DJ, Iori AP, Brown K, Torelli GF, Barberi W, Natalino F, De Propris MS, Girmenia C, Salvatori FM, Zelig O, FoĆ  R, Luzzatto L.

J Hematol Oncol. 2014 Mar 27;7:27. doi: 10.1186/1756-8722-7-27.

4.

The rate of spontaneous mutations in human myeloid cells.

Araten DJ, Krejci O, Ditata K, Wunderlich M, Sanders KJ, Zamechek L, Mulloy JC.

Mutat Res. 2013 Sep;749(1-2):49-57. doi: 10.1016/j.mrfmmm.2013.05.004. Epub 2013 Jun 6.

5.

Leukemic blasts with the paroxysmal nocturnal hemoglobinuria phenotype in children with acute lymphoblastic leukemia.

Araten DJ, Sanders KJ, Anscher D, Zamechek L, Hunger SP, Ibrahim S.

Am J Pathol. 2012 Nov;181(5):1862-9. doi: 10.1016/j.ajpath.2012.07.025. Epub 2012 Aug 30.

6.

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation.

Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ.

Blood Cancer J. 2012 Mar;2(3):e63. doi: 10.1038/bcj.2012.7. Epub 2012 Mar 23. No abstract available.

7.

Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature.

Araten DJ, Notaro R, Thaler HT, Kernan N, Boulad F, Castro-Malaspina H, Small T, Scaradavou A, Magnan H, Prockop S, Chaffee S, Gonsky J, Thertulien R, Tarquini R, Luzzatto L.

Haematologica. 2012 Mar;97(3):344-52. doi: 10.3324/haematol.2011.049767. Epub 2011 Dec 1. Review.

8.

Deletions of Xp22.2 including PIG-A locus lead to paroxysmal nocturnal hemoglobinuria.

O'Keefe CL, Sugimori C, Afable M, Clemente M, Shain K, Araten DJ, List A, Epling-Burnette PK, Maciejewski JP.

Leukemia. 2011 Feb;25(2):379-82. doi: 10.1038/leu.2010.274. Epub 2010 Nov 30. No abstract available.

PMID:
21116280
9.

A quantitative analysis of genomic instability in lymphoid and plasma cell neoplasms based on the PIG-A gene.

Araten DJ, Martinez-Climent JA, Perle MA, Holm E, Zamechek L, DiTata K, Sanders KJ.

Mutat Res. 2010 Apr 1;686(1-2):1-8. doi: 10.1016/j.mrfmmm.2009.11.012. Epub 2010 Jan 8.

10.

The use of PIG-A as a sentinel gene for the study of the somatic mutation rate and of mutagenic agents in vivo.

Peruzzi B, Araten DJ, Notaro R, Luzzatto L.

Mutat Res. 2010 Jul-Sep;705(1):3-10. doi: 10.1016/j.mrrev.2009.12.004. Epub 2009 Dec 24. Review.

PMID:
20034593
11.

Multiple myeloma involving skin and pulmonary parenchyma after autologous stem cell transplantation.

Yuan Y, Wieczorek R, Green DL, Cook P, Ballard H, Araten DJ.

J Hematol Oncol. 2009 Nov 13;2:48. doi: 10.1186/1756-8722-2-48.

12.

Spontaneously arising red cells with a McLeod-like phenotype in normal donors.

Araten DJ, Sanders KJ, Pu J, Lee S.

Mutat Res. 2009 Dec 1;671(1-2):1-5. doi: 10.1016/j.mrfmmm.2009.03.009. Epub 2009 Apr 2.

13.

Splenic infarction and subsequent splenic rupture in a patient with paroxysmal nocturnal hemoglobinuria and heparin-induced thrombocytopenia.

Magnan H, Kayton ML, DiMichele DM, Araten DJ, Kernan NA, Boulad F.

Pediatr Blood Cancer. 2009 Sep;53(3):472-4. doi: 10.1002/pbc.22058.

PMID:
19415735
14.

The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Araten DJ, Luzzatto L.

Blood. 2006 Jul 15;108(2):734-6. Epub 2006 Mar 16.

15.

A quantitative measurement of the human somatic mutation rate.

Araten DJ, Golde DW, Zhang RH, Thaler HT, Gargiulo L, Notaro R, Luzzatto L.

Cancer Res. 2005 Sep 15;65(18):8111-7. Erratum in: Cancer Res. 2005 Nov 15;65(22):10635.

16.
17.

Severe telomere shortening in patients with paroxysmal nocturnal hemoglobinuria affects both GPI- and GPI+ hematopoiesis.

Karadimitris A, Araten DJ, Luzzatto L, Notaro R.

Blood. 2003 Jul 15;102(2):514-6. Epub 2003 Mar 6.

18.

Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones.

Araten DJ, Bessler M, McKenzie S, Castro-Malaspina H, Childs BH, Boulad F, Karadimitris A, Notaro R, Luzzatto L.

Leukemia. 2002 Nov;16(11):2243-8.

19.

Association of clonal T-cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathogenetic link between T cells, aplastic anaemia and PNH.

Karadimitris A, Li K, Notaro R, Araten DJ, Nafa K, Thertulien R, Ladanyi M, Stevens AE, Rosenfeld CS, Roberts IA, Luzzatto L.

Br J Haematol. 2001 Dec;115(4):1010-4.

PMID:
11843843
20.

Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria.

Araten DJ, Swirsky D, Karadimitris A, Notaro R, Nafa K, Bessler M, Thaler HT, Castro-Malaspina H, Childs BH, Boulad F, Weiss M, Anagnostopoulos N, Kutlar A, Savage DG, Maziarz RT, Jhanwar S, Luzzatto L.

Br J Haematol. 2001 Nov;115(2):360-8. Review.

PMID:
11703336
21.

Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria.

Karadimitris A, Manavalan JS, Thaler HT, Notaro R, Araten DJ, Nafa K, Roberts IA, Weksler ME, Luzzatto L.

Blood. 2000 Oct 1;96(7):2613-20.

22.

Allogeneic bone marrow transplantation for paroxysmal nocturnal hemoglobinuria.

Araten DJ, Luzzatto L.

Haematologica. 2000 Jan;85(1):1-2. No abstract available.

23.
24.

In vitro alloreactivity against host antigens in an adult HLA-mismatched bone marrow transplant recipient despite in vivo host tolerance.

Araten DJ, Lawton T, Ferrara J, Antin JH, Milford E, Carpenter CB, Maziarz RT.

Transplantation. 1993 Jan;55(1):76-82.

PMID:
8420068

Supplemental Content

Loading ...
Support Center